A Th2 chemokine, TARC, produced by keratinocytes may recruit CLA+CCR4+ lymphocytes into lesional atopic dermatitis skin - PubMed (original) (raw)
A Th2 chemokine, TARC, produced by keratinocytes may recruit CLA+CCR4+ lymphocytes into lesional atopic dermatitis skin
C Vestergaard et al. J Invest Dermatol. 2000 Oct.
Free article
Abstract
Atopic dermatitis is an inflammatory skin disease in which the inflammation is characterized by the influx of lymphocytes into the dermis. It is generally believed that atopic dermatitis is a Th2-type disease, i.e., the T lymphocytes produce interleukin-4, interleukin-5, interleukin-10, and interleukin-13, although it has become evident in recent years that the cytokine profile in the skin changes during the course of the disease towards a Th1-Th2 mixed cytokine profile (interferon-gamma, tumor necrosis factor alpha, and interleukin-2). The lymphocytes that home into the skin express cutaneous lymphocyte-associated antigen, and it has recently been shown that most of the lymphocytes in this population express the chemokine receptor CCR4. CCR4 is the receptor for the CC chemokine TARC (thymus and activation regulated chemokine), and this chemokine is expressed predominantly by keratinocytes in the basal layer of the epidermis of lesional atopic dermatitis skin in mice. In humans, however, it was shown to be expressed in the endothelial cells of the dermis. We have examined the peripheral blood mononuclear cells of atopic dermatitis patients for the expression of cutaneous lymphocyte-associated antigen and CCR4 and compared them with peripheral blood mononuclear cells from normal controls. We found that the proportion of CLA+CCR4+ lymphocytes is upregulated in atopic dermatitis patients. In addition we have examined skin biopsies of lesional and non-lesional skin from atopic dermatitis patients and found that the keratinocytes, but not the endothelial cells, produce TARC in the lesional but not in the nonlesional skin. To gain insight in the stimulatory mechanisms for TARC production in keratinocytes, as previously observed in mice, we cultured HaCaT cells and found that interferon-gamma and tumor necrosis factor alpha work synergistically to induce TARC production. These observations suggest that the induction of TARC production in keratinocytes plays an important role in the late phase skin invasion by CCR4+CLA+ Th2-type lymphocytes in atopic dermatitis.
Similar articles
- Thymus- and activation-regulated chemokine (TARC/CCL17) induces a Th2-dominated inflammatory reaction on intradermal injection in mice.
Vestergaard C, Deleuran M, Gesser B, Larsen CG. Vestergaard C, et al. Exp Dermatol. 2004 Apr;13(4):265-71. doi: 10.1111/j.0906-6705.2004.00149.x. Exp Dermatol. 2004. PMID: 15086343 - Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity.
Kakinuma T, Nakamura K, Wakugawa M, Mitsui H, Tada Y, Saeki H, Torii H, Asahina A, Onai N, Matsushima K, Tamaki K. Kakinuma T, et al. J Allergy Clin Immunol. 2001 Mar;107(3):535-41. doi: 10.1067/mai.2001.113237. J Allergy Clin Immunol. 2001. PMID: 11240957 - IFN-gamma-inducible expression of thymus and activation-regulated chemokine/CCL17 and macrophage-derived chemokine/CCL22 in epidermal keratinocytes and their roles in atopic dermatitis.
Horikawa T, Nakayama T, Hikita I, Yamada H, Fujisawa R, Bito T, Harada S, Fukunaga A, Chantry D, Gray PW, Morita A, Suzuki R, Tezuka T, Ichihashi M, Yoshie O. Horikawa T, et al. Int Immunol. 2002 Jul;14(7):767-73. doi: 10.1093/intimm/dxf044. Int Immunol. 2002. PMID: 12096036 - Thymus and activation regulated chemokine (TARC)/CCL17 and skin diseases.
Saeki H, Tamaki K. Saeki H, et al. J Dermatol Sci. 2006 Aug;43(2):75-84. doi: 10.1016/j.jdermsci.2006.06.002. Epub 2006 Jul 21. J Dermatol Sci. 2006. PMID: 16859899 Review. - The potential role of allergen-specific sublingual immunotherapy in atopic dermatitis.
Mastrandrea F. Mastrandrea F. Am J Clin Dermatol. 2004;5(5):281-94. doi: 10.2165/00128071-200405050-00001. Am J Clin Dermatol. 2004. PMID: 15554729 Review.
Cited by
- IL-4 induces expression of TARC/CCL17 via two STAT6 binding sites.
Wirnsberger G, Hebenstreit D, Posselt G, Horejs-Hoeck J, Duschl A. Wirnsberger G, et al. Eur J Immunol. 2006 Jul;36(7):1882-91. doi: 10.1002/eji.200635972. Eur J Immunol. 2006. PMID: 16810739 Free PMC article. - Systemic and stratum corneum biomarkers of severity in infant atopic dermatitis include markers of innate and T helper cell-related immunity and angiogenesis.
McAleer MA, Jakasa I, Hurault G, Sarvari P, McLean WHI, Tanaka RJ, Kezic S, Irvine AD. McAleer MA, et al. Br J Dermatol. 2019 Mar;180(3):586-596. doi: 10.1111/bjd.17088. Epub 2018 Oct 4. Br J Dermatol. 2019. PMID: 30132823 Free PMC article. - Purpurin suppresses atopic dermatitis via TNF-α/IFN-γ-induced inflammation in HaCaT cells.
Oh JH, Kim SH, Kwon OK, Kim JH, Oh SR, Han SB, Park JW, Ahn KS. Oh JH, et al. Int J Immunopathol Pharmacol. 2022 Jan-Dec;36:3946320221111135. doi: 10.1177/03946320221111135. Int J Immunopathol Pharmacol. 2022. PMID: 35794850 Free PMC article. - Preventive effects of a novel herbal mixture on atopic dermatitis-like skin lesions in BALB/C mice.
Mechesso AF, Lee SJ, Park NH, Kim JY, Im ZE, Suh JW, Park SC. Mechesso AF, et al. BMC Complement Altern Med. 2019 Jan 18;19(1):25. doi: 10.1186/s12906-018-2426-z. BMC Complement Altern Med. 2019. PMID: 30658631 Free PMC article. - Bath Psoralen Plus UVA Therapy Suppresses Keratinocyte-Derived Chemokines in Pathogenetically Relevant Cells.
Kanayama Y, Torii K, Ikumi K, Morita A. Kanayama Y, et al. JID Innov. 2021 May 24;1(3):100027. doi: 10.1016/j.xjidi.2021.100027. eCollection 2021 Sep. JID Innov. 2021. PMID: 34909726 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources